Background/Aims: Progressive microvascular dysfunction in T2DM may impair the ability of cerebral vessels to supply blood to brain regions during local metabolic demand, thereby predisposing one to greater risk of dementia. Having previously demonstrated that resveratrol can enhance vasodilator function in the systemic circulation, we hypothesised that resveratrol would also benefit cerebral circulation. We aimed to determine the most efficacious dose of resveratrol to improve cerebral vasodilator responsiveness (CVR) in T2DM.
Method: In a double-blind, placebo-controlled crossover intervention trial, 36 well-controlled T2DM adults aged 40-80 years were randomised to consume a single dose of synthetic trans-resveratrol (0, 75, 150, 300 mg) at weekly intervals. Transcranial Doppler ultrasound was used to assess CVR to a hypercapnic stimulus, viz. breathing Carbogen gas (95% O 2 ; 5% CO 2 ) for 3 min, both before and 45 mins after resveratrol or placebo consumption. CVR was measured in both left and right middle cerebral arteries (MCA) and expressed as the percentage change in mean blood flow velocity from baseline to the peak velocity attained during the stimulus.
Results: Using repeated measures ANOVA, consumption of each resveratrol dose resulted in significant within-individual increases in CVR compared with placebo (75 mg: 13.8 ± 3.5%, p ¼ 0.001; 150 mg: 8.9 ± 3.5%, p ¼ 0.016; 300 mg: 13.7 ± 3.3%, p < 0.001). Background/Aims: About 2.5% of the general population show pseudoallergic reactions to salicylates (including aspirin). Patients with aspirinexacerbated respiratory disease (AERD) show symptomatic improvement on low salicylate diet. Aspirin sensitivity is detected through oral provocation test -contraindicated in anaphylactoid reaction. Food salicylate sensitivity is detected through highly restrictive and lengthy 'elimination and rechallenge diet' raising compliance issues. More recently, an in vitro assay, the basophil activation test (BAT), is reported to detect pseudoallergic reactions with high sensitivity and specificity. However, the results remain controversial. The aim of this study was to examine the ability of BAT to differentiate known salicylate sensitivity from healthy controls (HC). Methods: Peripheral blood of 10 AERD patients (2 males, 8 females), 10 HC (3 males, 7 females) was stimulated in vitro with aspirin (5, 2.5, 1.25, 0.6, 0.3, 0.15, 0.07 mg/ml). Flow cytometry was used to detect activated basophils (IgE+/CD63+). Stimulation index (SI) and percentage activation (% act) were used to determine basophil activation. Receiver-operator characteristics (ROC) were determined. Results: Mean SI in AERD was similar to HC for all concentrations [p-values ranged from 0.178 (0.6 mg/mL) to 0.800 (0.07 mg/mL), independent sample t-tests)]. Likewise, % act did not differ between the groups [pvalues ranged from 0.869 (2.5 mg/mL) to 0.498 (5 mg/mL)]. No cut-off values were able to discriminate the two subject groups (area-under-thecurve for ROC analyses < 0.5 for all). Background/Aims: TAS2R38 polymorphisms influence bitter taste phenotype. Both have been linked to alcohol consumption; however this has not been demonstrated in all cohorts tested. To date, this interaction has been studied in small cohorts (< 100 participants) with males and females combined, with not consideration of a potential gender dimorphism. Therefore we used a larger cohort to assess the gender specificity of this relationship. Methods: Blood was collected from patients undergoing routine colonoscopy (n ¼ 262). TAS2R38 genotype (A49P) was assessed using RFLP-PCR. Bitter taste phenotype (non-tasters vs. tasters) was determined using 6-n-propylthiouracil. Alcohol consumption was assessed using food frequency questionnaires. Frequencies of genotypes and phenotypes were compared by chi-squared tests. Pairwise comparisons were made using least squares means (adjusted for age and smoking status) and t-tests. Results: Distribution of genotype and phenotype did not vary between genders (c 2 ¼ 6.52, p ¼ 0.16 and c 2 ¼ 4.67, p ¼ 0.13, respectively).
Males were significantly older (60.4 ± 1.0 vs. 64.4 ± 1.2, p ¼ 0.009) and drank significantly more alcohol (5.0 ± 0.8 vs. 21.1 ± 2.6, p ¼ 0.0001). In males genotype and phenotype predicted alcohol intake, with carriers of the "P" variant and "tasters" drinking less (18.1 ± 3.1 g/day vs. 31.7 ± 4.6 g/ day, p ¼ 0.01 and 19.1 ± 2.9 vs. 34.2 ± 5.6, p ¼ 0.02, respectively Background/Aims: Soluble fibres are thought to lower blood cholesterol concentrations. A systematic review of the effect of pectin, a soluble fibre, on cholesterol concentrations was undertaken. Methods: EMBASE, PubMed and Cochrane CENTRAL were searched in December 2013. Randomised controlled trials lasting at least two weeks investigating increased consumption of pectin added to foods or as a supplement compared to a suitable control group and reporting at least total cholesterol concentrations in non-acutely ill subjects were included. Studies testing mixtures of fibres or whole foods were excluded because their effects could not be attributed to pectin. Study quality was assessed using the Risk of Bias criteria; high quality studies were double-blind and placebo-controlled. Meta-analysis was conducted using the generic inverse variance method. Results: Of the 115 articles retrieved, only seven met all inclusion criteria. These tested intakes of pectin between 9 and 36 g/day. The number of participants ranged from six to 66 and most studies were conducted in hypercholesterolaemic people. There was a mean reduction in blood total cholesterol concentration of 0.36 mmol/L (95% CI: -0.52 to -0.19 mmol/L, p < 0.001) and moderate heterogeneity (I 2 ¼ 45%) across all studies. Similar magnitudes of effect were seen in the four high quality studies and in the one, low quality, study conducted with normocholesterolaemic subjects. Conclusions: Daily consumption of at least 9 g pectin/day (a large amount compared to current average total fibre intakes) may reduce blood total cholesterol concentrations. Further studies are needed to confirm this effect, especially in normocholesterolaemic populations. 
